A Phase I/II Study of Foretinib in Combination with Lapatinib in Patients with Human Epidermal Growth Factor Receptor 2(HER2)Over-Expressing Metastatic Breast Cancer.

Trial Profile

A Phase I/II Study of Foretinib in Combination with Lapatinib in Patients with Human Epidermal Growth Factor Receptor 2(HER2)Over-Expressing Metastatic Breast Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2017

At a glance

  • Drugs Foretinib (Primary) ; Lapatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 07 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Sep 2014.
    • 21 Sep 2013 Lead centres updated as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top